EUVIMEDEUVIMED entdecken
Crossref

Impact of Folinic Acid Dosing on Efficacy and Toxicity of High-Dose Methotrexate in Central Nervous System Lymphoma

Arnon Haran, Noa Gross Even-Zohar, Michal Haran, Eyal Lebel, Shlomzion Aumann, Adir Shaulov, Moshe Gatt, Boaz Nachmias

Clinical Lymphoma Myeloma and Leukemia · 2024

DOI: 10.1016/j.clml.2023.10.012 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2024. Verfasst von Arnon Haran und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, POB 12000, Jerusalem, 91120, Israel. Elect…. Hauptthemen laut MEDLINE: Lymphoma, Central Nervous System Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: High-dose methotrexate (HDMTX)-based regimens are the treatment of choice in primary central nervous system lymphoma (PCNSL). Folinic acid (FA) rescue is used to mitigate the toxic effects of MTX on normal cells. However, the optimal dosing of FA in PCNSL remains uncertain. METHODS: We analyzed the relationship between FA dosing and treatment efficacy and toxicity in a cohort of 36 PCNSL patients treated at our institute between the years 2014 and 2022. A combination of univariate and multivariate analyses using known prognostic factors were used to determine the association between FA dosing and treatment outcomes. RESULTS: We found that higher per-treatment cumulative FA doses were associated with inferior progression-free survival (PFS), with a hazard ratio (HR) of 2.2 for each 100 mg/m2 increase in FA dose. We identified a threshold of 350 mg/m2/treatment, above which there was a significant reduction in PFS. Notably, lower FA doses did not result in increased toxicity. CONCLUSION: Our findings suggest that optimizing FA dosing to avoid very high rescue doses may improve treatment outcomes in PCNSL patients receiving HDMTX. Further prospective studies are warranted to validate these findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LymphomaCentral Nervous System NeoplasmsHumansMethotrexateLeucovorinAntimetabolites, AntineoplasticCentral Nervous SystemRetrospective Studies

Stichwörter der Autor:innen

CNS lymphomaProgression-free survivalRetrospective

Substanzen

MethotrexateLeucovorinAntimetabolites, Antineoplastic

Autor:innen und Institutionen

  • Department of Hematology, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, POB 12000, Jerusalem, 91120, Israel. Electronic address: arnon@hadassah.org.il.
  • Department of Hematology, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem, POB 12000, Jerusalem, 91120, Israel.
  • Department of Hematology, Kaplan Medical Center, Rehovot, Israel.

Zitieren

APA

Haran, A., Even-Zohar, N. G., Haran, M., Lebel, E., Aumann, S., Shaulov, A., Gatt, M., & Nachmias, B. (2024). Impact of Folinic Acid Dosing on Efficacy and Toxicity of High-Dose Methotrexate in Central Nervous System Lymphoma. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2023.10.012

Vancouver

Haran A, Even-Zohar NG, Haran M, Lebel E, Aumann S, Shaulov A, et al. Impact of Folinic Acid Dosing on Efficacy and Toxicity of High-Dose Methotrexate in Central Nervous System Lymphoma. Clinical Lymphoma Myeloma and Leukemia. 2024. doi:10.1016/j.clml.2023.10.012

BibTeX
@article{Haran2024,
  author = {Haran, Arnon and Even-Zohar, Noa Gross and Haran, Michal and Lebel, Eyal and Aumann, Shlomzion and Shaulov, Adir and Gatt, Moshe and Nachmias, Boaz},
  title = {Impact of Folinic Acid Dosing on Efficacy and Toxicity of High-Dose Methotrexate in Central Nervous System Lymphoma},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2024},
  doi = {10.1016/j.clml.2023.10.012}
}
Kostenlos starten →